Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874659 | 1.00 | DDB1 (0.43) | DDB1CRBNNOS1NOS2SLC18A3 | |
| SCHEMBL1274980 | 0.94 | DDB1 (0.44) | DDB1CRBNNOS1PDE4APDE4B | |
| SCHEMBL8177567 | 0.86 | DDB1 (0.52) | DDB1CRBNPDE4APDE4BPDE4C | |
| SCHEMBL3584879 | 0.86 | DDB1 (0.52) | DDB1CRBNPDE4APDE4BPDE4C | |
| SCHEMBL16796843 | 0.86 | DDB1 (0.52) | DDB1CRBNPDE4APDE4BPDE4C | |
| SCHEMBL7946211 | 0.84 | NPC1 (0.39) | DDB1CRBNPDE4APDE4BPDE4C | |
| SCHEMBL17515347 | 0.78 | KMT2A (0.36) | DDB1CRBN | |
| SCHEMBL17498024 | 0.78 | KMT2A (0.36) | DDB1CRBN | |
| SCHEMBL7631291 | 0.78 | NOS1 (0.39) | NOS1NOS2SLC18A3 | |
| SCHEMBL7671819 | 0.77 | DDB1 (0.54) | DDB1CRBNPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337575-B1 | MODIFIED POLYLACTAM | KONINK DSM N V (NL) | 2007-08-29 | — | — | EP | claimed |
| US-5338861-A | Cleaving lactam N-carboxylate or lactim O-carboxylate with elimination of carbon dioxide by heating in gas or liquid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | claimed |
| CN-113501786-B | Nylon monomer and preparation method thereof | 广西师范大学 | 2023-03-03 | — | — | CN | disclosed |
| WO-2021127643-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-108774172-A | A kind of preparation method of caprolactam and N substitution caprolactams | 铜仁学院 | 2018-11-09 | — | — | CN | disclosed |
| EP-1765805-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1615914-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1765805-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7491713-B2 | CGRP receptor antagonists | MERCK + CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1615914-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070287696-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0625145-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1994-11-23 | — | — | EP | disclosed |
| US-5338861-A | Cleaving lactam N-carboxylate or lactim O-carboxylate with elimination of carbon dioxide by heating in gas or liquid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| WO-1993015059-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| EP-0531673-A1 | Process for the preparation of N-substituted lactams | BAYER AG (DE) | 1993-03-17 | — | — | EP | disclosed |
| US-4680392-A | Substituted caprolactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4629787-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0046291-B1 | SUBSTITUTED CAPROLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287696-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | DDB1 1440/4885CRBN 3217/4885NOS1 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.